KATY
Financiado
Knowledge At the Tip of Your fingers Clinical Knowledge for Humanity
AI-empowered Personalized Medicine promises to find tailored, targeted, nearly hand-made cures for patients. Cancer treatment desperately needs boosters to find tailored, targeted cures for patients and Personalized Medicine can p...
AI-empowered Personalized Medicine promises to find tailored, targeted, nearly hand-made cures for patients. Cancer treatment desperately needs boosters to find tailored, targeted cures for patients and Personalized Medicine can play a crucial role. Tailored targeted therapies in cancer treatment are already a reality but the current practice of targeted therapies in cancer treatment has been derived with traditional methods of data analysis. AI-empowered Personalized Medicine may help to bring targeted therapies to the next level. However, no matter how precise it is, no matter how many lives it can save in principle, and no matter if it can utilize the entire medical knowledge. If clinicians do not understand its suggestions and decisions, AI-empowered Personalized Medicine will not be a game changer, clinicians will not use it to make everyday decisions and, thus, it is doomed to fail. Hence, the real challenge is building AI-empowered Personalized Medicine systems that can be accepted by clinicians and clinical researchers. In KATY, we grasp the above challenge and we propose an AI-empowered Personalized Medicine system that can bring medical AI-empowered knowledge to the tips of the fingers of clinicians and clinical researchers. The AI-empowered knowledge is a human interpretable knowledge that clinicians and clinical researchers can: understand, trust and effectively use in their everyday working routine. KATY is then a AI-empowered Personalized Medicine system built around two main components: A Distributed Knowledge Graph and A pool of eXplainable Artificial Intelligence predictors. As a stress test and due to the lack of personalized clinical responses, KATY will be experimented in a low prevalence and complex cancer: Clear cell renal cell carcinoma (ccRCC).
ver más
Duración del proyecto: 48 meses
Fecha Inicio: 2020-12-04
Fecha Fin: 2024-12-31
Fecha Fin: 2024-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-12-04
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
DT-TDS-04-2020:
AI for Genomics and Personalised Medicine
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
8M€
Líder del proyecto
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
950.97K€ |
Participante